Sentinel BioTherapeutics

What Sentinel BioTherapeutics does

Sentinel BioTherapeutics is a privately held, clinical-stage biotechnology company developing engineered cell-based cytokine factories for localized immunomodulation. The company's platform integrates synthetic biology, immunoengineering, and biomaterials to design living drug delivery systems that produce biologics in situ, with an initial therapeutic focus on ovarian cancer and stated optionality across autoimmune, inflammatory, and broader oncology indications. Underlying intellectual property originates from the laboratory of co-founder Omid Veiseh at Rice University, and lead scientific work has been published in journals including Nature Biomedical Engineering, Advanced Materials, and Science Advances.

The company is structured under the RBL LLC parent entity, was founded in 2026, and operates from the United States. Leadership comprises a CEO with prior venture capital experience (Rima Chakrabarti, ex-KdT Ventures Partner), a Head of Finance with extensive life sciences public-company experience (David Aubuchon, ex-SVP Finance at Obsidian, Sigilon, Aegerion, Ocata, and Sepracor), a VP of Operations focused on IND-enabling programs (Ryan Newman, ex-Avenge Bio and Sigilon), and senior clinical, regulatory, CMC, and manufacturing advisors drawn from Pfizer, Iovance, Replicate Bioscience, Alpine Immune Sciences, MD Anderson, and Baylor College of Medicine.

The company has no commercial products, no disclosed pricing, no disclosed funding rounds, no disclosed partnerships, and a 'Site under construction' public web presence, placing it firmly in the pre-clinical/early translational stage. Its business model is expected to follow the standard clinical-stage cell therapy path of advancing a lead program through IND-enabling studies and early clinical trials, with eventual commercialization through specialty oncology treatment centers and clinical trial sites rather than through traditional sales channels.

Name

Sentinel BioTherapeutics

Legal name

Sentinel BioTherapeutics

Website

https://sentinelbiotx.com

Company type

Private

Founded year

2026

Operating status

Operating

Headcount range

1–10 employees

Short description

Sentinel BioTherapeutics is a clinical-stage US biotechnology company developing engineered cell-based cytokine factories for localized immunomodulation, with an initial focus on ovarian cancer, built on cell therapy IP from co-founder Omid Veiseh's Rice University laboratory.

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

akta.pro secondary industries

Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Cell-based therapies
• Cytokine delivery
• Oncology drug development
• Engineered cell therapy
• Localized immunomodulation

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Core offering

Sentinel BioTherapeutics is developing engineered cell-based cytokine factory platforms for localized immunomodulation, using synthetic biology, immunoengineering, and biomaterials to design dynamic living drug delivery platforms. The company's initial focus is on ovarian cancer treatment, with broader applications in autoimmune, inflammatory, and cancer indications. The company is currently in early-stage clinical development with no named commercial products yet.

Product overview

Sentinel BioTherapeutics is developing engineered cell-based cytokine factory platforms for localized immunomodulation, with a focus on cell-based therapies for cancer treatment, particularly ovarian cancer. The company leverages synthetic biology, immunoengineering, and biomaterials to design living drug delivery platforms. The site currently displays a 'Site under construction' notice, and no specific named products or modules are fully described on the available web pages.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Obsidian Therapeutics: Obsidian develops engineered cell therapies with regulated cytokine activity for oncology and immunology; Sentinel's head of finance was SVP at Obsidian, and both companies use engineered cells as living drug factories to deliver cytokine payloads.
• Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor therapies for solid tumors and is a relevant peer for Sentinel as a cell therapy company applying engineered immune cells to treat solid tumor indications including ovarian cancer.
• Sigilon Therapeutics: Sigilon develops cell-based therapies encapsulating engineered cells for sustained delivery of biologics in chronic diseases; multiple Sentinel team members previously held operational and finance roles there, and its platform is structurally analogous to Sentinel's living drug delivery concept.
• Avenge Bio: Avenge Bio is a clinical-stage biotech developing engineered cell therapies for solid tumors, founded by Omid Veiseh and chaired by Paul Wotton (both Sentinel leadership); it is the closest platform analog with similar cytokine-driven cell therapy approaches.
• Marker Therapeutics: Marker Therapeutics develops multi-antigen specific T cell therapies for solid tumors and hematologic malignancies; it is directly comparable to Sentinel as a cell therapy developer targeting ovarian and other solid tumors with engineered immune cell approaches.
• Iovance Biotherapeutics: Iovance is the leading commercial cell therapy company in solid tumors, with FDA-approved TIL therapies; multiple Sentinel leaders (Zelanna Goldberg, Ryan Newman) previously held senior roles at Iovance, and the company develops cell-based treatments for solid tumor indications similar to Sentinel's ovarian cancer focus.
• Lyell Immunopharma: Lyell Immunopharma develops engineered T-cell therapies for solid tumors with emphasis on cell persistence and overcoming exhaustion; it is a peer for Sentinel as a cell therapy developer tackling solid tumor indications including gynecologic cancers.
• Ziopharm Oncology: Ziopharm develops cell and gene therapies for solid tumors with a focus on controllable immune system engagement; it is comparable to Sentinel as a cell therapy peer targeting solid tumors through engineered immune modulation.

Emerging players

• Replicate Bioscience: Replicate Bioscience develops self-replicating RNA therapeutics for cancer and other diseases; Sentinel's Zelanna Goldberg was CMO there, and while using a different modality (RNA vs. cell therapy), both are early-stage oncology biotechs working on novel immunomodulatory approaches.

Broad incumbents

• Alpine Immune Sciences: Alpine Immune Sciences developed immunology and inflammation therapeutics for autoimmune diseases and was acquired by Vertex; Sentinel's Zelanna Goldberg was CMO there, and Alpine represents a comparable immunology/autoimmune specialization with broader clinical capabilities beyond cell therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sentinel-biotx

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sentinel BioTherapeutics